There is no single best anxiety medication for Parkinson’s disease, because the right choice depends on which other Parkinson’s drugs you’re taking, whether your anxiety is tied to medication “off” periods, and how sensitive you are to motor side effects. That said, SSRIs (selective serotonin reuptake inhibitors) like sertraline are the most commonly used first-line option, and they have the strongest evidence for tolerability in this population. About one-third of people with Parkinson’s experience a clinically significant anxiety disorder, making it one of the most common non-motor symptoms of the disease.
Why Anxiety in Parkinson’s Is Different
Parkinson’s disease doesn’t just affect dopamine. It also disrupts serotonin, norepinephrine, and other chemical signaling systems in the brain that regulate mood and stress responses. This means anxiety in Parkinson’s isn’t simply a reaction to living with a difficult diagnosis. It has a biological basis in the same brain changes driving the motor symptoms.
Many people assume their anxiety flares only during “off” periods, when Parkinson’s medication wears off and movement becomes difficult. The relationship is actually more complex. A majority of patients report no clear connection between medication timing and anxiety at all, and those who do notice a link may feel anxious during “on” periods or during dyskinesia (involuntary movements) as well. A common pattern is a cycle of fearing an upcoming “off” state, noticing physical symptoms like breathlessness or dizziness, and then catastrophizing about falling, which can spiral into avoiding leaving the house entirely.
SSRIs: The Most Common First Choice
SSRIs work by increasing serotonin availability in the brain, which helps regulate both mood and anxiety. In clinical trials involving Parkinson’s patients, SSRIs produced a moderate but statistically significant reduction in depressive and anxious symptoms compared to placebo over roughly 12 weeks. Sertraline is the most frequently studied SSRI in Parkinson’s populations, appearing in multiple clinical trials across different comparison designs.
SSRIs are generally well tolerated, don’t worsen motor symptoms in most people, and address the depression that often accompanies Parkinson’s anxiety. The main drawback is that they take several weeks to reach full effect, and common side effects like nausea, sleep changes, or sexual dysfunction can be bothersome during that window.
The Serotonin Syndrome Question
If you take an MAO-B inhibitor for Parkinson’s, like rasagiline or selegiline, you’ve probably seen warnings about combining it with an SSRI. Product labels advise against this combination due to a theoretical risk of serotonin syndrome, a potentially serious condition caused by excess serotonin activity. In practice, though, the risk appears to be very low. A large retrospective study of over 1,500 Parkinson’s patients found zero cases of serotonin syndrome when rasagiline and an SSRI were used together. A survey across more than 4,500 patients on selegiline plus antidepressants identified only 11 possible cases, none fatal.
The current consensus is that SSRIs and MAO-B inhibitors can be used together when the SSRI dose is kept at the lower end of its therapeutic range and recommended doses aren’t exceeded. Still, this is a decision that requires careful coordination between your neurologist and whoever prescribes the anxiety medication.
SNRIs: Less Proven in Parkinson’s
SNRIs like venlafaxine boost both serotonin and norepinephrine. In theory, this dual action could be helpful, since both systems are disrupted in Parkinson’s. In practice, clinical trial data for SNRIs in Parkinson’s patients is limited. A network meta-analysis found no statistically significant difference between venlafaxine and placebo for reducing symptoms. That doesn’t mean SNRIs never work for individual patients, but the evidence base is thinner than for SSRIs.
MAO-B Inhibitors: A Parkinson’s Drug That May Help Anxiety
Rasagiline and selegiline are prescribed primarily to manage Parkinson’s motor symptoms by slowing the breakdown of dopamine in the brain. Cross-sectional studies have found that people taking these medications have a lower prevalence of anxiety disorders compared to those who don’t. If you’re already on one of these drugs, it may be contributing some anti-anxiety benefit. If you’re not, and anxiety is a significant problem, it’s worth discussing whether adding one could address both motor and mood symptoms.
Buspirone: Promising but Problematic
Buspirone is an anti-anxiety medication that works through serotonin receptors and was once considered especially attractive for Parkinson’s because early studies suggested it might also reduce levodopa-induced dyskinesias. In a clinical trial, participants on buspirone did show meaningful improvements on anxiety rating scales over 12 weeks.
The problem is motor side effects. In that same trial, 53% of participants on buspirone experienced worsened motor function, including freezing of gait, increased tremor, balance problems, dystonia, and more time spent in “off” states. Buspirone weakly blocks dopamine receptors, which is likely the culprit. The researchers concluded that tolerability concerns were significant enough that a large-scale efficacy trial wasn’t warranted without further study. Buspirone monotherapy (without other anxiety medications that might have muddied the results) still deserves investigation, but for now it’s not a straightforward recommendation.
Benzodiazepines: Common but Controversial
Benzodiazepines like lorazepam and clonazepam are fast-acting and effective for acute anxiety, which makes them tempting. They’re widely prescribed to Parkinson’s patients despite limited formal study in this group. The conventional concern is that they cause sedation, lightheadedness, and increase fall risk, all of which are already elevated in Parkinson’s.
Interestingly, one study comparing Parkinson’s patients on benzodiazepines to those not taking them found that the benzodiazepine group actually fell less often (about 17% versus 31%). This may reflect the fact that severe, untreated anxiety itself contributes to falls, or that the patients selected for benzodiazepines happened to have different risk profiles. The benzodiazepine group did perform worse on short-term memory tests, which is notable given that cognitive decline is already a concern in Parkinson’s. Cognitive side effects of long-term benzodiazepine use remain understudied in this population specifically.
Most clinicians view benzodiazepines as a short-term or as-needed option rather than a daily maintenance strategy for Parkinson’s anxiety. They can be useful for acute panic or situational anxiety, but the risks of dependence and cognitive dulling make them less suitable for ongoing use.
Low-Dose Quetiapine: An Off-Label Option
Quetiapine is an atypical antipsychotic primarily used for Parkinson’s-related psychosis (hallucinations or delusions), but many physicians prescribe low doses for anxiety and agitation as well. At the small doses typically used in Parkinson’s (often 25 to 75 mg), it causes minimal worsening of motor symptoms, with studies showing only 3% to 7% changes on motor function scales. The most common side effects at these doses are sedation, confusion, and drops in blood pressure when standing up. It’s not a first-line anxiety treatment, but it fills a role when anxiety co-occurs with sleep disturbance or mild psychotic symptoms.
Optimizing Parkinson’s Medications First
Before adding a new anxiety medication, it’s worth examining whether your current Parkinson’s treatment is optimized. If anxiety spikes during “off” periods, the most direct solution may be adjusting the timing or formulation of your dopaminergic therapy to reduce those gaps in coverage. Switching to extended-release formulations or adding an MAO-B inhibitor can smooth out the fluctuations that trigger anxiety episodes. For some people, this alone reduces anxiety enough that a separate medication becomes unnecessary.
When anxiety persists regardless of motor state, or is present even during “on” periods, a dedicated anxiety medication is more clearly needed. The typical approach starts with a low-dose SSRI like sertraline, titrated slowly to minimize side effects, with close monitoring over the first several weeks for both mood changes and any motor impact. If that’s insufficient or poorly tolerated, the options branch into the alternatives above based on individual circumstances.